Axovant Sciences Ltd. (NYSE:AXON) released its quarterly earnings results on Monday, August 7th. The biotechnology company reported ($0.65) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.53) by $0.12, Bloomberg Earnings reports.
Shares of Axovant Sciences (NYSE:AXON) traded down 0.499% during trading on Friday, hitting $20.945. 231,532 shares of the stock traded hands. The company has a 50 day moving average of $22.75 and a 200-day moving average of $19.39. The company’s market cap is $2.25 billion. Axovant Sciences has a 1-year low of $11.01 and a 1-year high of $26.49. Axovant Sciences also saw unusually large options trading on Wednesday. Stock traders acquired 11,388 put options on the stock. This represents an increase of 1,108% compared to the average volume of 943 put options.
TRADEMARK VIOLATION WARNING: This report was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are reading this report on another domain, it was illegally stolen and republished in violation of U.S. and international trademark & copyright legislation. The original version of this report can be accessed at https://www.com-unik.info/2017/08/18/axovant-sciences-ltd-axon-releases-quarterly-earnings-results-misses-estimates-by-0-12-eps-updated.html.
A number of equities research analysts recently weighed in on the stock. Cowen and Company reaffirmed an “outperform” rating and set a $30.00 price target on shares of Axovant Sciences in a report on Wednesday, June 21st. BidaskClub raised shares of Axovant Sciences from a “sell” rating to a “hold” rating in a report on Thursday, August 3rd. Jefferies Group LLC assumed coverage on shares of Axovant Sciences in a research report on Monday, July 10th. They issued a “buy” rating and a $40.00 price target on the stock. Zacks Investment Research downgraded shares of Axovant Sciences from a “hold” rating to a “sell” rating in a research report on Tuesday, July 11th. Finally, CIBC raised their price target on shares of Axovant Sciences from $26.00 to $30.00 and gave the stock an “outperform” rating in a research report on Wednesday, June 14th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and nine have given a buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $27.75.
Axovant Sciences Company Profile
Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.
What are top analysts saying about Axovant Sciences Ltd.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Axovant Sciences Ltd. and related companies.